Neuroimaging and CSF Biomarker Program

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

  • Developing novel PET ligands for clinical trials
  • Supporting novel CSF biomarkers
  • Validating innovative MRI approaches in larger cohorts
  • Developing novel measures of functional activity such as EEG

Peripheral biofluids and digital/ocular approaches are supported through the Diagnostics Accelerator RFP.

Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:

  • Neuronal loss
  • Vascular injury and blood-brain barrier integrity
  • Mitochondria and metabolic function
  • Protein misfolding
  • Oxidative stress
  • White matter changes
  • Lewy body dementia
  • Other novel targets supported by compelling biological rationale and connection to disease


Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
  • Biotechnology companies. Existing companies and new startups are both eligible.
  • NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).

Letter of Intent:

February 4, 2022
May 20, 2022
September 30, 2022

Full Proposal:

April 8, 2022
July 22, 2022
December 2, 2022

See Full Eligibility & Application Details

Agency Name: 
Alzheimer's Association
Contact Name:
Grant Amount: 
Up to $600,000, one year
Grant Location: 
External Deadline: 
Friday, February 4, 2022
Internal Deadline: 
Friday, January 28, 2022
Grant Type: 
Grant Area: 
Grant Eligibility: